Followers | 80 |
Posts | 3,532 |
Boards Moderated | 0 |
Alias Born | 06/04/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
wow that is commitment
I missed this post first time around
worth a re read
Thermo Fischer Scientific $TMO Major Focus on Precision Medicine / Treatments and Predictive Medicine going forward
Recent Article from August 2019 / as related to PRED
https://tinyurl.com/y4e587cj
Peter Silvester
serves as Senior Vice President and President of Life Sciences Solutions at Thermo Fisher Scientific.
Mr.Silvester provides executive oversight of Thermo Fisher’s biosciences, genetic sciences and clinical next-generation
sequencing businesses as well as life sciences finance, legal, HR, licensing and commercial supply functions. He is a Board Member of
Coriell Life Sciences and Executive Board Member of Biocom.
“Programs which engage all stakeholders academia, industry,
clinicians and patients – to deliver real-world evidence and economic value models to policy makers, regulatory agencies and payers, are what is needed to catalyze the adoption of precision medicine”
According to the U.S. Food & Drug Administration, pharmacogenomics is an
important part of precision medicine. FDA has an interest in determining how a person’s genetic makeup may affect their response to a drug, and how this can assist healthcare providers in “choosing a drug that is more likely to work, avoiding drugs that might have side effects, adjusting the dose of a drug, or determining if closer monitoring is needed.” says Peter Silvester
Incredible Post
Def worth the read
News out
PRED 10K / Eanings Release After Market Close CST 9/30
per TD Ameritrade
Jewish Holiday today - may explain why VOL is low
of Course not but there was much debate on this thread on what exactly the Listing Requirements were to uplist from OTC - Seems Like $2/$3 is the MIN price
No Wonder Thomas the Shorts / Manipulators were so adamant to keep us under $2
and delayed us as long as they could
Thx Thomas NASDAQ $2 or $3 Listing Requirements see Link
https://www.theventurealley.com/2012/04/post/
$2/share price — for at least five consecutive business days prior to approval, the security has a minimum closing price of at least $2 per share and the issuer has (A) market value of listed securities of at least $50M; (B) stockholders’ equity of at least $4M; and (C) market value of publicly held shares of at least $15M.
Great Advice TL thanks !!
I believe Thomas pointed out big deals take time to be signed off
Many legals / Compliance / IR / Management involved - many checks n balances and re checks and then double it with other parties involved
He referenced this wk could be something - but I am sure he is not the final word - in fact, hope they put a muzzle on him with all the "Teasers" he would float - prob best !!
happy to be here for a literal life changing co
certainly would not want to miss a blockbuster announcement[s]
cant deny the management / trust in management despite the recent poor pps
just need some forward guidance
Our Day is Close
Related - looks like the DoJ and SEC will be busy
Regulators Expand Already Massive Precious Metals Manipulation Probe To Other Markets
https://www.zerohedge.com/commodities/regulators-expand-already-massive-precious-metals-manipulation-probe-other-markets
Wed, 09/18/2019
Just two days after the DOJ took the unprecedented step of designating the JPMorgan precious metals trading desk as a "criminal enterprise" using unusually aggressive language which reminded legal experts of indictments utilizing the RICO Act, and which hopefully ended years of precious metal manipulation by the group formerly headed by Blythe Masters, CNBC now reports that the probe is set to spread significantly as Federal prosecutors and regulators "are expanding their already aggressive investigations of fraudulent precious metals trades at J.P. Morgan Chase to other U.S. markets and financial firms."
So far, the increased focus on spoofing has resulted in federal prosecutors bringing a total of 13 spoofing cases against 19 defendants in the past five years. Of those, eight have pleaded guilty, while seven are fighting the charges and awaiting trial.
Following the indictment of three J.P. Morgan precious metals traders on Monday, Assistant Attorney General Brian Benczkowski said that the Justice Department is not finished with its probes.
“Our investigation is ongoing, and we’re going to follow the facts wherever they lead whether it is across desks here or at any other bank or upwards into the financial institution,” Benczkowski said.
ya they would if they had just received their shares and got a massive to Market Discount
to cover their costs reduce any risk
see HELD at DTC is up at OTC Markets
so paper certs are appearing at the brokerages after months / years of being on the shelf
some may sell, some, part or all that is their right
I feel they may be kicking themselves soon for leaving XXXXX on the table
MM OTCX been offering at BEST ASK for over a week [seller]
MM VERT offering 100 share lots on the ASK for months [short IMO]
DOJ Accuses JPMorgan's Precious Metals Trading Desk Of Being A *Criminal* Enterprise
https://www.zerohedge.com/markets/three-jpmorgan-traders-charged-massive-gold-market-manipulation-fraud
PRED related - Hindenbergs last hit job
https://hindenburgresearch.com/bloom-energy-a-clean-energy-darling-wilting-to-its-demise/
Symbol - BE - down 20% today
more shareholder hardships caused by these scumbags
while free and fair / balanced press is the American Way
unfair coordinated / manipulated shorts attacks are not
hoping they get what they deserve in the end
BRAD SIGNS !!!! Thank you Thomas for Sharing
The Big Question now - What the Heck did he sign ??
Predictive Technology Group's CEO Bradley Robinson signing in Hong Kong, e.g., after five months of corporate, financial, and scientific due diligence. PRED press announcements are coming soon. Note: I said "press announcements" not singular "announcement."
LINK to Photo Posted by ThomasHBS-HLS
https://tinyurl.com/yxzp5w3z
PRED RELATED - IPO of TXG today
10X GENOMICS, INC.
Life Sciences / Cell Gene Therapy co UP to 40+% in IPO debut
Lots of continued Love for BioTech / Life Science Companies in General
Would be interested how they compare to PRED
https://www.10xgenomics.com/
Related - WSGR Event Preventative Medicine for Biotech Companies: Lessons from Life Sciences Securities Litigation
Wilson Sonsini Goodrich & Rosati / WSGR
Wednesday, September 18, 2019
https://www.wsgr.com/email/Boston_Events/2019/LifeSciences-Securities-Litigation_Boston_Web.html
$PRED NEWS
PREDICTIVE TECHNOLOGY GROUP ACCELERATES RESEARCH SAMPLE COLLECTIONS TO SUPPORT DEVELOPMENT OF PERSONALIZED MOLECULAR DIAGNOSTICS AND CLINICAL THERAPIES
https://yesinternational.com/predictive-technology-group-accelerates-research-sample-collections-to-support-development-of-personalized-molecular-diagnostics-and-clinical-therapies/
Subsidiary Predictive Laboratories hits milestone with 2,500 samples collected and processed since acquiring CLIA operations in March 2019; four new research sample collection initiatives set to begin this quarter
SALT LAKE CITY, Aug 20, 2019 (GLOBE NEWSWIRE via COMTEX) -- SALT LAKE CITY, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (otc pink:PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories(TM) has collected over 2,500 DNA samples along with comprehensive medical records since acquiring its CLIA operations in March 2019. Predictive is broadening its research initiatives by acquiring new sample collections in chronic pain, pregnancy complications, autism, and both female and male infertility.
Research is conducted following strict protocols approved by external Institutional Review Boards. Hundreds of individuals each month have voluntarily consented to share their medical histories and DNA samples for ongoing research. All research subjects are informed that their samples will be used in aggregate to develop new commercial diagnostic and therapeutic products. To ensure privacy, research samples and datasets are deidentified and securely stored.
Personalized medicine and the development of new therapeutics are expected to play a critical role in human health. Access to high-quality biospecimens from Predictive's biobank will be crucial for furthering the Company's biomedical and translational research, and ultimately its development of personalized molecular diagnostics and clinical therapies. Current sample collection efforts are designed to strategically augment Predictive's existing library of over 300,000 DNA samples that the Company believes will produce valuable insights into future research and development projects.
The development of effective diagnostic and treatment products requires identification of genetic markers that are useful for early detection, prevention, and personalized treatment of specific medical conditions. Genetic discoveries lead to insights into the cause and progression of disease and often suggest novel means of treating serious chronic conditions. Modern genetic research requires large numbers of well-characterized samples; one set for discovery, another independent set for replication, a third for validation, and a fourth to prove the clinical utility.
"The ability to discover specific genetic markers related to the diagnosis, prognosis, and therapeutic response for disease targets can help Predictive find solutions that could transform medical care," said Bradley Robinson, CEO of Predictive Technology Group. "A crucial requirement for personalized medicine is the availability of an extensive collection of both human diseased and healthy samples with well-documented medical records.
"Through investment in our biobank initiatives and collaboration with others who have relevant research collections, we reached this new collection milestone of 2,500 samples very rapidly and we continue to build on our database," he added. "At Predictive Laboratories, we have state-of-the-art capabilities for automated DNA extraction, sample handling, and high-throughput genotyping and sequencing that support our planned development of breakthrough diagnostics and therapeutics."
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a high complexity molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). The group recently launched its novel test for women experiencing infertility, ARTguide(TM), to selected collaborators. ARTguide(TM) is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other genetic conditions. The test is expected to change the way that Assisted Reproductive Technologies (ART), such as in vitro fertilization (IVF), are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person's risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com, Predrx.com, Predictivebiotech.com, and Predictivelabs.com.
https://www.marketwatch.com/press-release/predictive-technology-group-accelerates-research-sample-collections-to-support-development-of-personalized-molecular-diagnostics-and-clinical-therapies-2019-08-20?siteid=nbsh
Thomas .. from your extensive research
what is your estimate of how many shares are Naked Short vs Actual Short
as you know most major discount brokers DO NOT Allow Short trades of Pink Sheet or Penny Stocks - i.e. TD Ameritrade / E*Trade / Scott Trade - Cannot confirm Interactive Brokers
and any idea of how much these crooks profited from this ongoing conspiracy to Naked Short
imminent
adjective
1. Meaning
about to happen.
synonyms: impending, at hand, close, near, approaching, fast approaching, coming, forthcoming, on the way, about to happen, upon us, in store, in the offing, in the pipeline, on the horizon, in the air, in the wind, brewing, looming, looming large; threatening, menacing; expected, anticipated; in the cards
"there was speculation that an up list was imminent"
YOU DONT GET TO DO THE WALK THRU AT NASDAQ
UNLESS U R APPROVED
HENCE WE MUST BE APPROVED
Brian who is this ?
was a VP - they could have said its not happening or its delayed or we are going another direction instead says "Should be approved any Day"
FWIW - spoke to a PRED employee a VP locally - says "NASD should be approved any day now"
$ELGL Gold Prices To Hit $1,575 In 3 Months, $1,600 In 6 Months - Goldman Sachs
https://www.kitco.com/news/2019-08-12/Gold-Prices-To-Hit-1-575-In-3-Months-1-600-In-6-Months-Goldman-Sachs.html#.XVG0yau1Qi4.twitter
$ELGL 17.7 million Tonnes Valued at $16 Billion Euro it appears
Assets include
GOLD AU / SILVER AG / Zinc ZN / COPPER CU / LEAD PB
http://www.clarinova.eu/images/files/certificate-0013-0017.pdf
http://www.clarinova.eu/images/files/extract-from-dekra-valuatio.pdf
up 21% - stay tuned https://elementglobal.com/
$PRED - Stem Cells Market Size is Projected to be Around US$ 297 Billion By 2022
https://www.marketwatch.com/press-release/stem-cells-market-size-is-projected-to-be-around-us-297-billion-by-2022-2018-06-19
The global stem cells market is expected to grow at an incredible CAGR of 25.5% from 2015 to 2022 and reach a market value of US$297 billion by 2022. The emergence of Induced Pluripotent Stem (iPS) cells as an alternative to ESCs (embryonic stem cells), growth of developing markets, and evolution of new stem cell therapies represent promising growth opportunities for leading players in this sector.
The stem cell therapy market includes large number of players that are involved in development of stem cell therapies of the treatment of various diseases. Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are the key players involved in the development of stem cell therapies across the globe.
Due to the increased funding from Government and Private sector and rising global awareness about stem cell therapies and research are the main factors which are driving this market. A surge in therapeutic research activities funded by governments across the world has immensely propelled the global stem cells market. However, the high cost of stem cell treatment and stringent government regulations against the harvesting of stem cells are expected to restrain the growth of the global stem cells market.
You Can Browse Full Report @: https://www.marketresearchengine.com/reportdetails/global-stem-cells-market-analysis-report
This report will definitely help you make well informed decisions related to the stem cell market. The stem cell therapy market includes large number of players that are involved in development of stem cell therapies of the treatment of various diseases. Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are the key players involved in the development of stem cell therapies across the globe.
PRED Has Amazing Employees all Exceptional Backgrounds / Educations
https://www.linkedin.com/company/predictive-biotech-inc/
https://www.linkedin.com/company/predictive-technology-group-inc/
Bryt Christensen, M.D. Named in todays PR
https://www.southwestspineandpain.com/physicians/bryt-christensen-md
Bigger Health Care / BitTech valuations on Nasdaq